Inmune Bio, Inc. SEC filings INMB

Inmune Bio, Inc. has 601 filings in SEC EDGAR's recent list, going back to Jul 13, 2017. Its latest annual report, Form 10-K, was filed on Mar 30, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 5, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Oct 29, 2026 (material agreement, unregistered share sale, regulation fd disclosure). The company's fiscal year ends on December 31.

Form Description Filed Period
DEF 14A Proxy statement Apr 23, 2026 Jun 16, 2026
DEF 14A Proxy statement Oct 14, 2025 Nov 18, 2025
PRE 14A Preliminary proxy statement Oct 3, 2025 Oct 3, 2025
DEFA14A Additional proxy material Apr 25, 2025 —
DEF 14A Proxy statement Apr 21, 2025 May 28, 2025
DEF 14A Proxy statement May 29, 2024 Jul 19, 2024
DEF 14A Proxy statement Apr 21, 2023 Jun 1, 2023
DEF 14A Proxy statement Apr 19, 2022 Jun 1, 2022
DEF 14A Proxy statement Apr 26, 2021 Jun 1, 2021
DEF 14A Proxy statement Aug 21, 2020 Sep 30, 2020
DEF 14A Proxy statement Aug 9, 2019 Jul 25, 2019
PRE 14A Preliminary proxy statement Jul 29, 2019 Jul 25, 2019

Showing 12 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.

Company profile

Industry
Biological Products, (No Diagnostic Substances) (SIC 2836)
Listed as
INMB (Nasdaq)
Fiscal year ends
December 31
Incorporated in
NV
Headquarters
Boca Raton, FL
SEC filer status
Non-accelerated filer, Smaller reporting company
SEC CIK
1711754

Other Biological Products, (No Diagnostic Substances) companies

All 182 Biological Products, (No Diagnostic Substances) companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.